SECTION 06 / ABOUT
About this publication
An independent editorial project indexing the Semax research record. Not a clinic, not a pharmacy, not a vendor. Editorial commentary on publicly available science.
SECTION 01 / WHAT RX SEMAX IS
Rx Semax is an independent editorial project that publishes summaries of the peer-reviewed research literature on Semax (MEHFPGP), the synthetic ACTH(4-10) analog developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. We are not a clinic. We do not employ clinicians, pharmacists, or any healthcare staff, and we do not provide medical advice. We do not manufacture, sell, distribute, or broker any product. We are not affiliated with any vendor, manufacturer, or research-chemical supplier. Our work is editorial commentary on publicly available science.
The 'Rx' in the domain name is editorial framing — it reflects Semax's prescription status in the Russian Federation and Ukraine and the regulatory-dossier register of this publication. It is not a claim that Semax is or can be prescribed in the United States. Semax is not approved by the FDA and cannot be lawfully prescribed by a US-licensed physician for filling at a standard US pharmacy.
The site's visual register — stenciled section markers, bilingual EN/RU stamp chips in the masthead, regulatory-stamp callouts treating jurisdictional caveats as customs imprints — is a deliberate editorial position. The Semax record sits across multiple regulatory jurisdictions with different statuses in each. The visual language is intended to make those status differences visible at a glance, rather than buried in fine-print disclaimers.
SECTION 02 / EDITORIAL STANDARDS
Every quantitative claim on this site cites a specific published study identified by PMID, DOI, or canonical source URL. Where a finding has only been replicated in Russian-language sources, the citation flags the language. Where a Russian-language source has been reconstructed from secondary sources and not independently verified in PubMed, the citation flags that uncertainty explicitly [14].
We do not invent doses. We do not recommend doses. We document what specific investigators administered in specific published studies and in what specific contexts — preclinical species, route, duration. The figures in /dosage are research-context values reported in the cited literature; they are not human-dose recommendations and they are not US prescribing labels [1][3][14].
We do not link to other sites in our portfolio. We do not link to vendors, research-chemical suppliers, or any commercial source. The outbound links on this site go only to primary published research — PubMed, PMC, Springer Nature, ScienceDirect, and journals of record. The references page is the canonical index.
This publication is an independent editorial digest of the Semax research record — not a clinic, not a pharmacy, and not a vendor. The editorial standard is precision: every claim traces to a citation, every citation carries a PMID or DOI, and every jurisdictional status is stated plainly.
SECTION 03 / WHAT THIS SITE IS NOT
Rx Semax is not a telehealth platform. We do not offer consultations. We do not refer to clinicians. The domain modifier 'Rx' is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services.
We do not sell Semax. We do not broker introductions to vendors. We do not maintain affiliate relationships with research-chemical suppliers, peptide synthesis labs, or any commercial entity in the Semax supply chain.
We are not the developer of Semax. The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the Myasoedov group; the principal Russian clinical investigators are Gusev, Skvortsova, Martynov, Polunin, and colleagues. This site is editorial commentary on their published work, not the product of any laboratory or clinical program of our own.